CoChat

Understanding Duchenne muscular dystrophy-associated brain pathology

Open access
Verhaeg, Minou A. T., Govaarts, Rosanne, van Putten, Maaike · 2025 · Disease Models & Mechanisms

The DOI matches its Crossref record; 203 of the 204 references it cites were found in a registry or an index; none of the 273 sources its claims cite is checked for support yet.

Abstract

The most common neuromuscular disorder, Duchenne muscular dystrophy (DMD), is caused by mutations in the DMD gene, resulting in a lack of dystrophin. In addition to severe and progressive muscle wasting, a subset of individuals with DMD experience, to largely varying extents, behavioural and cognitive deficits, including a lower IQ, and neurological comorbidities, such as autism spectrum disorder, obsessive compulsive disorder and attention deficit hyperactivity disorder. Neuroimaging studies in individuals with DMD have identified widespread pathology, including structural, physiological and connective alterations. DMD mouse models exhibit a number of DMD-associated behavioural traits, including anxiety, social deficits and learning disabilities, and have been used to investigate DMD brain pathology. Although there are currently no therapies to treat DMD brain pathology, genetic approaches are being developed to restore dystrophin expression. In particular, the exon skipping approach shows promise in ameliorating certain DMD-associated behavioural deficits in preclinical settings. However, the therapeutic potential of postnatal restoration of dystrophin isoforms involved in neurodevelopment is unknown. Furthermore, challenges such as low dystrophin restoration efficacy and translatability from DMD mouse models to the clinic remain to be addressed.

Overview

CoChat Summary

TL;DR

This review synthesizes human and preclinical evidence that Duchenne muscular dystrophy (DMD) involves brain pathology beyond muscle, with cognitive/behavioural deficits in ∼30% of individuals and widespread neuroimaging, neurochemical and synaptic alterations. It highlights DMD mouse models and preclinical exon-skipping approaches that partially restore brain dystrophin and improve some behavioural phenotypes, while noting major gaps in efficacy, translatability and postnatal restoration of neurodevelopmental isoforms.

Key findings

  • About 30% of individuals with DMD have cognitive/behavioural deficits; average IQ is reported as mean=84.76 versus general population mean=100, with comorbidities including ASD ∼6%, OCD ∼7%, ADHD ∼16% and epileptic seizures 5%.
  • Neuroimaging in DMD shows decreased total brain volume and global grey matter reductions, white matter microstructural deficits (increased diffusivity, lower fractional anisotropy), default mode network hyperconnectivity, reduced cerebral blood flow and altered motor cortex function; some changes are more pronounced in individuals lacking both Dp427 and Dp140, but findings are inconsistent.
  • DMD mouse models show behavioural phenotypes including severe restraint-induced freezing in mdx/bl10 lasting at least 1 h, anxiety that worsens with loss of Dp140 and all isoforms, learning/memory deficits, social deficits and altered ultrasonic vocalizations; DMD-null mice also show restless behaviour and altered day/night rhythms.
  • Preclinical exon skipping in mdx/bl10 and mdx52 mice restores dystrophin at low levels (e.g. 5–25% in several studies; exon 53 skipping restored 1% Dp427 and 5% Dp140 in one study) and can improve fear, anxiety or ASD-like behaviour, but postnatal restoration of Dp140 and Dp427p remains of unknown therapeutic value.

Methods

  • Design: narrative review of DMD-associated brain pathology, animal models and therapy development, with a focus on exon skipping for brain dystrophin restoration.
  • Data/sample: published human post-mortem, neuroimaging, neuropsychological and clinical literature, plus preclinical studies in mouse, rat, dog and pig DMD models; no primary data were generated.
  • Main analysis: qualitative synthesis of cited studies, including summary tables of behavioural deficits in DMD mouse models (Table 1) and exon-skipping approaches in the DMD mouse brain (Table 2).

Limitations

  • Stated in the paper: clinical neuroimaging studies are limited by small sample sizes (often ∼15 participants), underrepresentation of distal mutations affecting multiple/all dystrophin isoforms, variability in corticosteroid regimens/dosages/duration, and largely correlative findings that cannot establish causality.
  • Stated in the paper: DMD mouse models are usually steroid-naïve, differ from humans in brain complexity and dystrophin isoform spatiotemporal expression, and face challenges of low dystrophin restoration efficacy and limited translatability to the clinic.
  • Evident from the text: as a narrative review, it does not systematically appraise or meta-analyze the literature, and it repeatedly notes conflicting or inconclusive findings across studies, including inconsistent anxiety, depressive-like behaviour, memory and neuroimaging results.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1242/dmm.052302

Cites

203 of 203 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. The human DMD gene and the different dystrophin isoforms. The DMD gene contains seven promotors (indicated by the arrows), which give rise to different dystrophin proteins expressed in diverse tissues (indicated by the pictograms above the arrows). Dp427c, Dp427p, Dp140, Dp71 and Dp40 are expressed in the brain. There is one deletion hotspot, indicated by the lightning icons (exon 42-55). Only Dp427 has an N-terminal actin-binding domain (left dark-blue block). Each isoform consists of multiple spectrin-like repeats (light-blue ovals), proline-rich hinge domains (grey blocks) and a C-terminal domain. The C-terminal domain of Dp40 is truncated. Dp427c, Dp427m, Dp427p, Dp260, Dp116, Dp71 and Dp40 have a unique first protein-encoding exon (black block). The unique first exon of Dp140 is not translated because the translation start site is located in exon 51.
Fig. 1. The human DMD gene and the different dystrophin isoforms. The DMD gene contains seven promotors (indicated by the arrows), which give rise to different dystrophin proteins expressed in diverse tissues (indicated by the pictograms above the arrows). Dp427c, Dp427p, Dp140, Dp71 and Dp40 are expressed in the brain. There is one deletion hotspot, indicated by the lightning icons (exon 42-55). Only Dp427 has an N-terminal actin-binding domain (left dark-blue block). Each isoform consists of multiple spectrin-like repeats (light-blue ovals), proline-rich hinge domains (grey blocks) and a C-terminal domain. The C-terminal domain of Dp40 is truncated. Dp427c, Dp427m, Dp427p, Dp260, Dp116, Dp71 and Dp40 have a unique first protein-encoding exon (black block). The unique first exon of Dp140 is not translated because the translation start site is located in exon 51.CC BY · PubMed Central
Fig. 2. Exon skipping therapy in DMD. (A) In a healthy situation, all exons are translated, and dystrophin isoforms are synthesized. (B) In the mdx52 model, exon 52 of the Dmd gene is deleted, which disrupts the reading frame, thereby preventing the synthesis of Dp427 and Dp140, whereas that of Dp71/Dp40 remains unaffected. (C) Skipping of exon 51 restores the disrupted reading frame, thereby allowing the expression of shortened, but partially functional, Dp427 isoforms. Because exon 51 contains the translational start site of Dp140, this isoform is not expressed. (D) When exon 53 is skipped instead, shortened Dp427 and Dp140 proteins are produced. (E) In the mdx/bl10 and mdx/bl6 models, a point mutation in exon 23 of the Dmd gene leads to disruption of the reading frame and a premature stop codon, thereby preventing synthesis of Dp427, whereas the other isoforms remain unaffected. (F) Skipping of exon 23 restores the reading frame and enables the synthesis of a shortened Dp427. AON, antisense oligonucleotide; DMD, Duchene muscular dystrophy.
Fig. 2. Exon skipping therapy in DMD. (A) In a healthy situation, all exons are translated, and dystrophin isoforms are synthesized. (B) In the mdx52 model, exon 52 of the Dmd gene is deleted, which disrupts the reading frame, thereby preventing the synthesis of Dp427 and Dp140, whereas that of Dp71/Dp40 remains unaffected. (C) Skipping of exon 51 restores the disrupted reading frame, thereby allowing the expression of shortened, but partially functional, Dp427 isoforms. Because exon 51 contains the translational start site of Dp140, this isoform is not expressed. (D) When exon 53 is skipped instead, shortened Dp427 and Dp140 proteins are produced. (E) In the mdx/bl10 and mdx/bl6 models, a point mutation in exon 23 of the Dmd gene leads to disruption of the reading frame and a premature stop codon, thereby preventing synthesis of Dp427, whereas the other isoforms remain unaffected. (F) Skipping of exon 23 restores the reading frame and enables the synthesis of a shortened Dp427. AON, antisense oligonucleotide; DMD, Duchene muscular dystrophy.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 4 Not valid · 159 Not checked · 78 Own results and interpretations

101 more claims

Create a free account to see all 241 claims and to verify the 249 references still open.

See all claims — free account
  • Probably not a substantial claim. 32
  • It may state two separate claims as one. 107
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 203 references

Cited by

See all 5

Metadata

Authors
Verhaeg, M. A. T., Govaarts, R., & van Putten, M.
Affiliations
Leiden University Medical Center (NL)
Corresponding author
  • Govaarts, Rosanne
  • van Putten, Maaike
Venue
Disease Models & Mechanisms
Published
2025-07-01
Volume
18
Issue
7
ISSN
  • 1754-8403 (ISSN-L)
  • 1754-8411
OpenAlex
W4412820802
Cited by
5
References
204
Citations by year
2026: 5
FWCI
0.32
Type
journal article
Language
en
Open access
Locations
  • Disease Models & Mechanisms (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Horizon 2020 Framework Programme (847826)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Keywords
Duchenne muscular dystrophy, neuropathology, dystrophin, DMD gene mutations, cognitive impairment, autism spectrum disorder, obsessive-compulsive disorder, attention deficit hyperactivity disorder, anxiety, social dysfunction, learning disabilities, exon skipping, dystrophin isoforms, brain development, behavioural deficits
MeSH terms
Animals, Brain, Disease Models, Animal, Humans, Dystrophin, Muscular Dystrophy, Duchenne, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Understanding Duchenne muscular dystrophy-associated brain pathology. https://app.cochat.ai/papers/10.1242/dmm.052302
The paper
Verhaeg, M. A. T., Govaarts, R., & van Putten, M. (2025). Understanding Duchenne muscular dystrophy-associated brain pathology. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.052302

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.